Agendia Launches BluePrint™ Expanding Breast Cancer Product Offering

Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint®, and TargetPrint™, has been expanded with BluePrint ™ to report important additional information on tumor subtypes.

Source: Agendia